Mansour Mai, Mansour Samar, Mortada Nahed D, Abd Elhady Seham S
Department of Pharmaceutics, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Drug Dev Ind Pharm. 2008 Jul;34(7):744-52. doi: 10.1080/03639040801926030.
The purpose of this study was to develop poloxamer-based in situ gelling formulations of ciprofloxacin hydrochloride (HCl) aiming at prolonging corneal contact time, controlling drug release, enhancing ocular bioavailability, and increasing patient compliance. The in situ forming gels were prepared using different concentrations of poloxamer 407 (P407) and poloxamer 188 (P188). Mucoadhesives such as hydroxypropylmethyl cellulose (HPMC) or hydroxyethyl cellulose (HEC) were added to the formulations to enhance the gel bioadhesion properties. The prepared formulations were evaluated for their in vitro drug release, sol-gel transition temperature, rheological behavior, and mucoadhesion force. The in vivo antimicrobial efficacy of selected ciprofloxacin HCl in situ gelling formulations was studied on infected rabbit's eyes and compared with that of the marketed conventional eye drops. The gelation temperature of the prepared formulations ranged from 28.00 to 34.03 degrees C. Increasing the concentrations of P407, HPMC, and HEC increased the viscosity and mucoadhesion force of the preparations and decreased the in vitro drug release. Ciprofloxacin HCl in situ forming gel formulae composed of P407/P188/HPMC (18/13/1.5%, wt/wt), and P407/P188/HEC (18/13/0.5%, wt/wt) showed optimum release and mucoadhesion properties and improved ocular bioavailability as evidenced by an enhanced therapeutic response compared with the marketed conventional eye drops.
本研究的目的是开发基于泊洛沙姆的盐酸环丙沙星原位凝胶制剂,旨在延长角膜接触时间、控制药物释放、提高眼部生物利用度并增强患者依从性。使用不同浓度的泊洛沙姆407(P407)和泊洛沙姆188(P188)制备原位形成凝胶。将诸如羟丙基甲基纤维素(HPMC)或羟乙基纤维素(HEC)等粘膜粘附剂添加到制剂中以增强凝胶的粘膜粘附特性。对所制备的制剂进行体外药物释放、溶胶-凝胶转变温度、流变学行为和粘膜粘附力评估。在感染的兔眼上研究了所选盐酸环丙沙星原位凝胶制剂的体内抗菌功效,并与市售传统眼药水进行比较。所制备制剂的胶凝温度范围为28.00至34.03摄氏度。增加P407、HPMC和HEC的浓度会增加制剂的粘度和粘膜粘附力,并降低体外药物释放。由P407/P188/HPMC(18/13/1.5%,重量/重量)和P407/P188/HEC(18/13/0.5%,重量/重量)组成的盐酸环丙沙星原位形成凝胶配方显示出最佳的释放和粘膜粘附特性,并改善了眼部生物利用度,与市售传统眼药水相比,治疗反应增强证明了这一点。